Hub : Traits :

Gout (self-reported)

179 significantly associated models · 57 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 2 26592429 28607344 18 2 1.1e-23 3.8e-28 4.5e-01 100 AC074117.10 PPM1G
2 3 52174970 53623102 1 1 7.9e-08 1.6e-10 4.9e-04 70 TMEM110
3 4 9370814 11156010 4 10 3.2e-70 2.9e-88 NaN NaN RP11-448G15.3 SLC2A9 WDR1
4 4 87655053 90061475 6 9 4.4e-62 1.5e-197 1.2e-74 63 ABCG2 HERC6 NUDT9 PKD2 PPM1K
5 6 25266147 26689223 2 1 1.1e-16 9.4e-20 1.5e-04 83 U91328.21
6 7 71935903 73738067 2 1 6.1e-12 5.0e-12 1.0e+00 100 MLXIPL
7 10 60712592 62185494 1 1 4.8e-11 6.6e-13 3.7e-03 84 SLC16A9
8 11 63305184 66456387 11 9 1.1e-16 4.5e-21 NaN NaN ARL2 CCDC88B FKBP2 NRXN2 OVOL1 SNX15 VEGFB ZFPL1
9 12 56776586 58705075 3 1 1.7e-12 1.2e-14 1.6e-03 83 KIF5A
10 12 121820692 123326374 1 1 1.4e-09 1.0e-10 2.3e-02 88 MLXIP
11 15 75444033 76878362 1 1 6.4e-09 1.5e-06 5.9e-01 99 UBE2Q2
12 16 69112398 70669292 1 1 2.3e-07 6.1e-08 5.2e-02 87 WWP2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Crohns Disease (2017) 1.49 3 1 3.0 0.00 1.0e+00 AC074117.10 CCDC88B PPM1G
Irritable Bowel Disease (IBD) 1.13 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Verbal and Numeric Reasoning (VNR) 1.48 2 1 3.0 0.00 1.0e+00 TMEM110 WWP2
Breast Cancer 2.03 2 1 3.0 0.00 1.0e+00 HERC6 PPM1K
Body Mass Index (BMI) (2010) 1.76 1 0 0.0 0.00 1.0e+00 MLXIP
Crohns Disease (2012) 1.28 1 0 0.0 0.00 1.0e+00 CCDC88B
Fasting Glucose 2.26 2 2 6.1 0.00 1.0e+00 AC074117.10 PPM1G
HDL Cholesterol 1.87 3 2 6.1 0.00 1.0e+00 KIF5A MLXIPL ZFPL1
LDL Cholesterol 1.10 1 0 0.0 0.00 1.0e+00 OVOL1
Primary Biliary Cirrhosis 1.51 1 0 0.0 0.00 1.0e+00 CCDC88B
Schizophrenia 1.54 1 0 0.0 0.00 1.0e+00 TMEM110
Triglycerides 14.13 4 4 12.1 -0.96 3.9e-02 AC074117.10 KIF5A MLXIPL PPM1G
Ulcerative Colitis 1.20 1 0 0.0 0.00 1.0e+00 TMEM110
Blood Eosinophil Count 0.89 5 2 6.1 -0.69 1.9e-01 FKBP2 MLXIPL OVOL1 SNX15 WWP2
Blood Platelet Count 2.12 9 7 21.2 -0.69 3.9e-02 AC074117.10 KIF5A MLXIP MLXIPL NUDT9 OVOL1 PPM1G SLC2A9 UBE2Q2
Blood Red Count 1.11 7 4 12.1 -0.28 5.1e-01 KIF5A MLXIP SLC2A9 SNX15 TMEM110 UBE2Q2 WWP2
Blood White Count 1.89 6 3 9.1 -0.97 1.7e-03 AC074117.10 KIF5A MLXIPL PPM1G SLC16A9 WWP2
Heel T-Score 1.62 7 3 9.1 -0.50 1.7e-01 ABCG2 CCDC88B HERC6 OVOL1 PKD2 PPM1K SLC16A9
BMI 2.04 9 5 15.2 0.50 1.2e-01 HERC6 KIF5A MLXIP MLXIPL NRXN2 PPM1K SLC2A9 WWP2 ZFPL1
Height 1.13 10 8 24.2 0.65 3.1e-02 AC074117.10 ARL2 MLXIP MLXIPL NUDT9 OVOL1 PPM1G SLC16A9 SLC2A9 WWP2
Waist Hip Ratio (WHR) 1.02 2 1 3.0 0.00 1.0e+00 MLXIP MLXIPL
Systolic Blood Pressure 1.16 6 0 0.0 -0.98 6.0e-04 AC074117.10 MLXIP NRXN2 OVOL1 PPM1G SLC16A9
Smoking Status 1.05 2 0 0.0 0.00 1.0e+00 CCDC88B NRXN2
Allergy or Eczema 1.65 4 1 3.0 -0.39 6.1e-01 AC074117.10 MLXIP OVOL1 PPM1G
Cardiovascular Disease 1.73 6 2 6.1 -1.00 1.2e-05 AC074117.10 CCDC88B MLXIPL OVOL1 PPM1G SNX15
Hypothyroidism (self reported) 1.77 2 1 3.0 0.00 1.0e+00 CCDC88B MLXIP
Respiratory disease 0.89 1 1 3.0 0.00 1.0e+00 KIF5A
Type 2 Diabetes (T2D) 2.02 3 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G WWP2
Lung FEV1/FVC ratio 0.79 2 1 3.0 0.00 1.0e+00 PPM1K SLC2A9
Lung FVC 1.11 3 2 6.1 0.00 1.0e+00 HERC6 SLC2A9 WWP2
Neuroticism 0.95 1 1 3.0 0.00 1.0e+00 TMEM110
Chronotype (morning person) 0.75 1 0 0.0 0.00 1.0e+00 WWP2
Hair Pigment 0.24 5 3 9.1 -0.37 5.4e-01 AC074117.10 KIF5A MLXIPL OVOL1 PPM1G
Tanning 0.32 4 1 3.0 1.00 2.5e-04 AC074117.10 MLXIPL PPM1G TMEM110
Hand grip strength (left) 1.32 1 0 0.0 0.00 1.0e+00 WWP2
Number of treatments/medications taken 1.71 3 0 0.0 0.00 1.0e+00 AC074117.10 OVOL1 PPM1G
Sensitivity / hurt feelings 0.94 1 0 0.0 0.00 1.0e+00 U91328.21
Relative age of first facial hair 1.27 3 0 0.0 0.00 1.0e+00 AC074117.10 ARL2 OVOL1
Ever used hormone-replacement therapy (HRT) 1.69 1 0 0.0 0.00 1.0e+00 PPM1G
Medication: Metformin 1.23 1 0 0.0 0.00 1.0e+00 AC074117.10
Impedance of leg (right) 1.10 5 1 3.0 0.89 4.5e-02 AC074117.10 HERC6 MLXIP MLXIPL PPM1K
Leg fat-free mass (left) 1.68 7 3 9.1 -0.84 1.7e-02 AC074117.10 HERC6 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Trunk fat percentage 1.20 3 2 6.1 -0.65 3.5e-01 MLXIP NRXN2 WWP2
Hand grip strength (right) 0.88 1 0 0.0 0.00 1.0e+00 WWP2
Fed-up feelings 1.28 1 0 0.0 0.00 1.0e+00 CCDC88B
Taking other prescription medications 1.67 1 0 0.0 0.00 1.0e+00 CCDC88B
Age when periods started (menarche) 1.26 1 1 3.0 0.00 1.0e+00 WWP2
Heel bone mineral density (BMD) T-score, automated (left) 1.31 3 0 0.0 0.00 1.0e+00 OVOL1 PKD2 PPM1K
Qualifications: CSEs or equivalent 1.97 1 0 0.0 0.00 1.0e+00 RP11-448G15.3
High blood pressure 1.27 2 0 0.0 0.00 1.0e+00 CCDC88B OVOL1
Hayfever, allergic rhinitis or eczema 1.96 4 1 3.0 0.95 5.4e-02 AC074117.10 OVOL1 PPM1G U91328.21
Medication: Levothyroxine sodium 1.60 1 0 0.0 0.00 1.0e+00 CCDC88B
Sitting height 1.75 8 6 18.2 -0.93 6.8e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21 WWP2
Body mass index (BMI) 1.68 6 2 6.1 -0.61 1.5e-01 HERC6 MLXIP MLXIPL NRXN2 WWP2 ZFPL1
Impedance of leg (left) 1.25 6 2 6.1 0.69 1.3e-01 AC074117.10 HERC6 MLXIP MLXIPL PPM1K SLC2A9
Leg predicted mass (left) 1.69 7 3 9.1 -0.84 1.7e-02 AC074117.10 HERC6 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Trunk fat mass 1.37 4 2 6.1 -0.62 2.6e-01 HERC6 MLXIP NRXN2 WWP2
Waist circumference 1.46 4 2 6.1 -0.44 5.6e-01 MLXIP NRXN2 PPM1K WWP2
Nervous feelings 1.06 1 1 3.0 0.00 1.0e+00 TMEM110
Frequency of tenseness / restlessness in last 2 weeks 0.98 1 0 0.0 0.00 1.0e+00 TMEM110
Had menopause 3.79 2 2 6.1 0.00 1.0e+00 AC074117.10 PPM1G
Forced vital capacity (FVC) 1.20 2 1 3.0 0.00 1.0e+00 PPM1K WWP2
Heel bone mineral density (BMD) T-score, automated (right) 1.28 3 0 0.0 0.00 1.0e+00 OVOL1 PKD2 PPM1K
Heart attack 1.03 1 0 0.0 0.00 1.0e+00 KIF5A
Allergy 1.53 2 2 6.1 0.00 1.0e+00 KIF5A OVOL1
Diabetes (self-reported) 1.95 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Medication: Simvastatin 1.63 1 0 0.0 0.00 1.0e+00 AC074117.10
Fluid intelligence score 1.19 2 1 3.0 0.00 1.0e+00 TMEM110 WWP2
Neuroticism score 0.93 1 0 0.0 0.00 1.0e+00 TMEM110
Weight 1.64 6 2 6.1 -0.89 8.0e-03 AC074117.10 HERC6 MLXIP MLXIPL NRXN2 U91328.21
Impedance of arm (right) 1.44 4 2 6.1 0.75 2.5e-01 AC074117.10 MLXIPL SLC2A9 ZFPL1
Arm fat percentage (right) 1.43 4 2 6.1 -0.47 4.2e-01 HERC6 MLXIP NRXN2 WWP2
Trunk fat-free mass 1.78 7 5 15.2 -0.98 9.9e-05 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21
Hip circumference 2.06 5 4 12.1 -0.70 1.2e-01 HERC6 MLXIP MLXIPL NRXN2 WWP2
Alcohol intake versus 10 years previously 2.12 1 1 3.0 0.00 1.0e+00 AC074117.10
Worrier / anxious feelings 0.97 1 0 0.0 0.00 1.0e+00 TMEM110
Forced expiratory volume in 1-second (FEV1) 0.98 2 1 3.0 0.00 1.0e+00 PPM1K WWP2
Pulse rate 1.23 1 0 0.0 0.00 1.0e+00 AC074117.10
Serious illness, injury or assault of a close relative in last 2 years 1.96 2 0 0.0 0.00 1.0e+00 NRXN2 WWP2
Asthma 1.08 2 1 3.0 0.00 1.0e+00 KIF5A U91328.21
Medication: Cholesterol lowering 1.77 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Forced expiratory volume in 1-second (FEV1), Best measure 0.95 2 1 3.0 0.00 1.0e+00 U91328.21 WWP2
Impedance of arm (left) 1.52 4 2 6.1 0.76 2.4e-01 AC074117.10 MLXIPL SLC2A9 ZFPL1
Arm fat mass (right) 1.54 4 2 6.1 -0.59 2.9e-01 HERC6 MLXIP NRXN2 WWP2
Trunk predicted mass 1.80 7 5 15.2 -0.98 1.0e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21
Standing height 1.35 9 7 21.2 -0.74 1.5e-02 AC074117.10 ARL2 MLXIP NUDT9 PPM1G SLC16A9 SLC2A9 U91328.21 WWP2
Peak expiratory flow (PEF) 0.78 1 0 0.0 0.00 1.0e+00 WWP2
Headache pain in last month 1.30 1 0 0.0 0.00 1.0e+00 NUDT9
Medication for cholesterol, blood pressure or diabetes 1.26 1 0 0.0 0.00 1.0e+00 AC074117.10
Hypothyroidism/myxoedema (self-reported) 1.58 1 0 0.0 0.00 1.0e+00 CCDC88B
Medication: Amlodipine 1.47 1 0 0.0 0.00 1.0e+00 OVOL1
Forced vital capacity (FVC), Best measure 1.26 2 1 3.0 0.00 1.0e+00 SLC16A9 WWP2
Body fat percentage 1.27 3 2 6.1 -0.64 3.6e-01 MLXIP NRXN2 WWP2
Leg fat percentage (right) 1.42 4 2 6.1 -0.67 2.1e-01 MLXIP NRXN2 WWP2 ZFPL1
Arm fat-free mass (right) 1.90 7 4 12.1 -0.97 3.8e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21
Comparative body size at age 10 1.27 3 0 0.0 0.00 1.0e+00 AC074117.10 MLXIP OVOL1
Medication for pain relief, constipation, heartburn 1.70 1 0 0.0 0.00 1.0e+00 PPM1G
Medication: Allopurinol 39.94 26 21 63.6 1.00 7.5e-44 ABCG2 AC074117.10 ARL2 CCDC88B FKBP2 HERC6 KIF5A MLXIP MLXIPL NRXN2 NUDT9 OVOL1 PKD2 PPM1G PPM1K RP11-448G15.3 SLC16A9 SLC2A9 SNX15 TMEM110 U91328.21 UBE2Q2 VEGFB WDR1 WWP2 ZFPL1
Whole body fat mass 1.49 4 2 6.1 -0.63 2.6e-01 HERC6 MLXIP NRXN2 WWP2
Leg fat mass (right) 1.61 5 2 6.1 -0.66 1.5e-01 HERC6 MLXIP NRXN2 WWP2 ZFPL1
Arm predicted mass (right) 1.87 7 4 12.1 -0.97 4.2e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21
Pulse rate, automated reading 1.75 4 1 3.0 0.99 6.0e-03 AC074117.10 MLXIPL PPM1G WWP2
Alcohol intake frequency. 2.64 5 2 6.1 0.98 4.0e-03 AC074117.10 MLXIPL PPM1G UBE2Q2 WWP2
Comparative height size at age 10 1.17 6 3 9.1 -0.78 3.8e-02 AC074117.10 MLXIP PPM1G SLC16A9 SLC2A9 U91328.21
Number of full sisters 0.97 1 0 0.0 0.00 1.0e+00 SLC2A9
Suffer from 'nerves' 1.11 1 0 0.0 0.00 1.0e+00 TMEM110
Supplements: Vitamin C 1.06 1 0 0.0 0.00 1.0e+00 WWP2
Hypertension (Self-reported) 1.28 2 0 0.0 0.00 1.0e+00 CCDC88B OVOL1
Forced expiratory volume in 1-second (FEV1), predicted 0.84 1 0 0.0 0.00 1.0e+00 SLC16A9
Whole body fat-free mass 1.74 7 5 15.2 -0.97 3.4e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21
Leg fat-free mass (right) 1.56 7 3 9.1 -0.84 1.9e-02 AC074117.10 HERC6 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Arm fat percentage (left) 1.58 4 2 6.1 -0.46 4.4e-01 HERC6 MLXIP NRXN2 WWP2
Mood swings 1.74 1 0 0.0 0.00 1.0e+00 TMEM110
Diabetes diagnosed by doctor 1.96 3 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G WWP2
Medication for cholesterol 1.48 1 0 0.0 0.00 1.0e+00 AC074117.10
Back pain experienced in last month 1.35 1 0 0.0 0.00 1.0e+00 NUDT9
Mineral and other dietary supplements 1.57 1 0 0.0 0.00 1.0e+00 KIF5A
Asthma (self-reported) 1.08 1 1 3.0 0.00 1.0e+00 KIF5A
Osteoporosis (self-reported) 1.47 1 0 0.0 0.00 1.0e+00 PKD2
Forced expiratory volume in 1-second (FEV1), predicted percentage 0.94 1 0 0.0 0.00 1.0e+00 WWP2
Whole body water mass 1.76 7 5 15.2 -0.97 3.3e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21
Leg predicted mass (right) 1.56 7 3 9.1 -0.84 1.8e-02 AC074117.10 HERC6 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Arm fat mass (left) 1.58 4 2 6.1 -0.59 3.0e-01 HERC6 MLXIP NRXN2 WWP2
Number of self-reported non-cancer illnesses 2.08 2 0 0.0 0.00 1.0e+00 AC074117.10 CCDC88B
Medication: Blood pressure 1.56 1 1 3.0 0.00 1.0e+00 OVOL1
Pain type(s) experienced in last month: Hip pain 2.15 1 0 0.0 0.00 1.0e+00 MLXIP
Supplements: Fish oil (including cod liver oil) 1.94 1 0 0.0 0.00 1.0e+00 KIF5A
High cholesterol (Self-reported) 3.39 2 2 6.1 0.00 1.0e+00 AC074117.10 PPM1G
Medication: Bendroflumethiazide 1.18 1 0 0.0 0.00 1.0e+00 NUDT9
Medication: Lisinopril 1.02 1 0 0.0 0.00 1.0e+00 MLXIP
Medication: Atorvastatin 2.41 2 1 3.0 0.00 1.0e+00 AC074117.10 PPM1G
Ever smoked 1.91 1 0 0.0 0.00 1.0e+00 NRXN2
Basal metabolic rate 1.70 8 4 12.1 -0.87 5.1e-03 AC074117.10 HERC6 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21
Leg fat percentage (left) 1.29 4 1 3.0 -0.69 2.0e-01 MLXIP NRXN2 WWP2 ZFPL1
Arm fat-free mass (left) 1.77 7 4 12.1 -0.97 3.4e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21
Diastolic blood pressure, automated reading 0.72 1 0 0.0 0.00 1.0e+00 OVOL1
Vascular/heart problems diagnosed by doctor 1.23 2 0 0.0 0.00 1.0e+00 CCDC88B OVOL1
Cholesterol lowering medication 1.82 1 1 3.0 0.00 1.0e+00 AC074117.10
Basal cell carcinoma (self-reported) 1.30 1 0 0.0 0.00 1.0e+00 CCDC88B
Heart attack/myocardial infarction (self-reported) 1.05 1 0 0.0 0.00 1.0e+00 KIF5A
Impedance of whole body 1.37 5 2 6.1 0.63 2.5e-01 AC074117.10 MLXIPL PPM1K SLC2A9 ZFPL1
Leg fat mass (left) 1.56 5 2 6.1 -0.68 1.4e-01 HERC6 MLXIP NRXN2 WWP2 ZFPL1
Arm predicted mass (left) 1.82 7 4 12.1 -0.97 3.1e-04 AC074117.10 MLXIP MLXIPL NUDT9 PPM1G SLC16A9 U91328.21

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 9 0.2578 1.47
GTEx Adipose Visceral Omentum 8 0.3929 1.63
GTEx Adrenal Gland 2 0.1373 1.42
GTEx Artery Aorta 6 0.2015 1.38
GTEx Artery Coronary 4 0.3381 1.45
GTEx Artery Tibial 9 0.2393 1.44
GTEx Brain Caudate basal ganglia 0 0.0000 1.23
GTEx Brain Cerebellar Hemisphere 1 0.0672 1.33
GTEx Brain Cerebellum 1 0.0505 1.36
GTEx Brain Cortex 1 0.0966 1.30
GTEx Brain Frontal Cortex BA9 0 0.0000 1.32
GTEx Brain Hippocampus 0 0.0000 1.31
GTEx Brain Hypothalamus 0 0.0000 1.26
GTEx Brain Nucleus accumbens basal ganglia 1 0.1156 1.35
GTEx Brain Putamen basal ganglia 0 0.0000 1.28
GTEx Breast Mammary Tissue 2 0.1013 1.45
GTEx Breast Mammary Tissue (Male) 2 0.1676 1.31
GTEx Breast Mammary Tissue (Female) 1 0.0608 1.38
GTEx Cells EBV-transformed lymphocytes 2 0.1405 1.43
GTEx Cells Transformed fibroblasts 6 0.1429 1.33
GTEx Colon Sigmoid 3 0.2052 1.48
GTEx Colon Transverse 6 0.2907 1.50
GTEx Esophagus Gastroesophageal Junction 2 0.1384 1.38
GTEx Esophagus Mucosa 6 0.1807 1.45
GTEx Esophagus Muscularis 5 0.1547 1.46
GTEx Heart Atrial Appendage 0 0.0000 1.32
GTEx Heart Left Ventricle 1 0.0654 1.36
GTEx Liver 1 0.1395 1.48
GTEx Lung 5 0.1740 1.41
GTEx Muscle Skeletal 5 0.1730 1.38
GTEx Nerve Tibial 9 0.2083 1.43
GTEx Ovary 1 0.1101 1.40
GTEx Pancreas 2 0.1225 1.33
GTEx Pituitary 1 0.0897 1.33
GTEx Prostate 1 0.1198 1.41
GTEx Skin Not Sun Exposed Suprapubic 4 0.1627 1.42
GTEx Skin Sun Exposed Lower leg 5 0.1374 1.43
GTEx Small Intestine Terminal Ileum 1 0.2169 1.49
GTEx Spleen 2 0.1417 1.40
GTEx Stomach 1 0.0688 1.32
GTEx Testis 5 0.1585 1.40
GTEx Thyroid 7 0.1750 1.42
GTEx Uterus 0 0.0000 1.34
GTEx Vagina 1 0.1575 1.48
GTEx Whole Blood 4 0.2007 1.47
METSIM Adipose 7 0.1518 1.36
NTR Blood 2 0.0833 1.41
ROSMAP Brain Pre-frontal Cortex 11 0.2505 1.39
YFS Blood 4 0.0866 1.29
CommonMind Brain Pre-frontal Cortex 7 0.1302 1.33
TCGA Breast Tumor 1 0.1304 1.73
TCGA Breast Normal 9 0.2139 1.30
TCGA Ovarian Tumor 2 0.0684 1.22
TCGA Prostate Tumor 3 0.0867 1.37